Vascular complications and changes in body mass index in Japanese type 2 diabetic patients with abdominal obesity
暂无分享,去创建一个
T. Funahashi | I. Shimomura | S. Fukuda | A. Imagawa | T. Yasuda | H. Nishizawa | N. Maeda | J. Kozawa | Susumu Kashine | K. Okita | A. Hirata | Tetsuhiro Kitamura | T. Okada | T. Hibuse | H. Nagao | M. Tsugawa | T. Kimura
[1] Jarett D. Berry,et al. Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults , 2012, Obesity.
[2] T. Funahashi,et al. Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes , 2012, Cardiovascular Diabetology.
[3] T. Assimes,et al. Central obesity is important but not essential component of the metabolic syndrome for predicting diabetes mellitus in a hypertensive family-based cohort. Results from the Stanford Asia-pacific program for hypertension and insulin resistance (SAPPHIRe) Taiwan follow-up study , 2012, Cardiovascular Diabetology.
[4] H. Farzad,et al. Prognostic significance of the Complex "Visceral Adiposity Index" vs. simple anthropometric measures: Tehran lipid and glucose study , 2012, Cardiovascular Diabetology.
[5] T. Sanke,et al. International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values , 2012, Diabetology International.
[6] T. Funahashi,et al. Absolute value of visceral fat area measured on computed tomography scans and obesity-related cardiovascular risk factors in large-scale Japanese general population (the VACATION-J study) , 2012, Annals of medicine.
[7] T. Funahashi,et al. Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes , 2011, Cardiovascular Diabetology.
[8] T. Funahashi,et al. Insulin‐secretion capacity in normal glucose tolerance, impaired glucose tolerance, and diabetes in obese and non‐obese Japanese patients , 2011, Journal of diabetes investigation.
[9] Weiping Jia,et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. , 2009, JAMA.
[10] T. Funahashi,et al. Metabolic impact of adipose and hepatic glycerol channels aquaporin 7 and aquaporin 9 , 2008, Nature Clinical Practice Endocrinology &Metabolism.
[11] 岡内 幸義. Reduction of Visceral Fat Is Associated With Decrease in the Number of Metabolic Risk Factors in Japanese Men , 2008 .
[12] P Zimmet,et al. Ethnic comparisons of the cross‐sectional relationships between measures of body size with diabetes and hypertension , 2008, Obesity reviews : an official journal of the International Association for the Study of Obesity.
[13] D. Tanné,et al. Effects of Peroxisome Proliferator-Activated Receptor Ligands, Bezafibrate and Fenofibrate, on Adiponectin Level , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[14] Ho-Young Son,et al. Epidemic obesity and type 2 diabetes in Asia , 2006, The Lancet.
[15] S. Kihara,et al. Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. , 2006, Kidney international.
[16] M. Kawai,et al. Increases in body mass index, even within non‐obese levels, raise the risk for Type 2 diabetes mellitus: a follow‐up study in a Japanese population , 2005, Diabetic medicine : a journal of the British Diabetic Association.
[17] S. Oh,et al. Cut-off point of BMI and obesity-related comorbidities and mortality in middle-aged Koreans. , 2004, Obesity research.
[18] S. Kihara,et al. Adiponectin as a biomarker of the metabolic syndrome. , 2004, Circulation journal : official journal of the Japanese Circulation Society.
[19] Emile R Mohler,et al. Peripheral arterial disease: identification and implications. , 2003, Archives of internal medicine.
[20] M. Matsuda,et al. Coordinated regulation of fat-specific and liver-specific glycerol channels, aquaporin adipose and aquaporin 9. , 2002, Diabetes.
[21] S. Kihara,et al. Adiponectin in essential hypertension. , 2002, Journal of nephrology.
[22] Jonathan Krakoff,et al. Adiponectin and development of type 2 diabetes in the Pima Indian population , 2002, The Lancet.
[23] R. Bergman,et al. Extreme insulin resistance of the central adipose depot in vivo. , 2002, Diabetes.
[24] M. Matsuda,et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. , 2001, Diabetes.
[25] G. Lewis,et al. Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance. , 2001, Trends in cardiovascular medicine.
[26] W. Hiatt,et al. Medical treatment of peripheral arterial disease and claudication. , 2001, The New England journal of medicine.
[27] Y. Akanuma,et al. Risk factors for the development of diabetic retinopathy in Japanese type 2 diabetic patients. , 2001, Diabetes research and clinical practice.
[28] Bruce M. Spiegelman,et al. Obesity and the Regulation of Energy Balance , 2001, Cell.
[29] Stephen J. Aldington,et al. UKPDS 50: Risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis , 2001, Diabetologia.
[30] A. Kimmel,et al. On the Control of Lipolysis in Adipocytes , 1999, Annals of the New York Academy of Sciences.
[31] A. Bennett,et al. The assembly of triacylglycerol-rich lipoproteins: an essential role for the microsomal triacylglycerol transfer protein , 1998, British Journal of Nutrition.
[32] Uk-Prospective-Diabetes-Study-Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.
[33] S. Yamashita,et al. Enhanced expression of hepatic acyl‐coenzyme A synthetase and microsomal triglyceride transfer protein messenger RNAs in the obese and hypertriglyceridemic rat with visceral fat accumulation , 1998, Hepatology.
[34] W. Fujimoto. Overview of Non‐insulin‐dependent Diabetes Mellitus (NIDDM) in Different Population Groups , 1996, Diabetic medicine : a journal of the British Diabetic Association.
[35] S. Yamashita,et al. Enhanced expression of PAI–1 in visceral fat: Possible contributor to vascular disease in obeisty , 1996, Nature Medicine.
[36] B. Spiegelman,et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. , 1995, The Journal of clinical investigation.
[37] T Nakamura,et al. Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. , 1994, Atherosclerosis.
[38] P. Wahl,et al. Plasma insulin levels in Japanese and Japanese-American men with type 2 diabetes may be related to the occurrence of cardiovascular disease. , 1989, Diabetes research and clinical practice.
[39] H. Yki-Järvinen,et al. Clinical benefits and mechanisms of a sustained response to intermittent insulin therapy in type 2 diabetic patients with secondary drug failure. , 1988, The American journal of medicine.
[40] P. Björntorp,et al. Regional differences and effect of weight reduction on human fat cell metabolism , 1979, European journal of clinical investigation.
[41] T. Funahashi,et al. The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. , 2011, Journal of atherosclerosis and thrombosis.
[42] J. Shaw,et al. Global estimates of the prevalence of diabetes for 2010 and 2030. , 2010, Diabetes research and clinical practice.
[43] E. Oda. New criteria for 'obesity disease' in Japan. , 2006, Circulation journal : official journal of the Japanese Circulation Society.
[44] H. Minuk,et al. Metabolic syndrome. , 2005, Journal of insurance medicine.
[45] C. Conti. Cardiovascular diabetology. , 1999, Clinical cardiology.
[46] S. Colagiuri,et al. The Diabetes Control and Complications Trial , 1983, Henry Ford Hospital medical journal.
[47] A. Kissebah,et al. Relation of body fat distribution to metabolic complications of obesity. , 1982, The Journal of clinical endocrinology and metabolism.